跳转至内容
Merck
CN

HPA023904

Anti-RAB11FIP1 antibody produced in rabbit

Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab1

别名:

Anti-Rab-coupling protein, Anti-Rab11 family-interacting protein 1, Anti-Rab11-FIP1

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
Human Protein Atlas Number:
Conjugate:
unconjugated
Clone:
polyclonal
Application:
immunofluorescence
immunohistochemistry
Species reactivity:
human
Citations:
7
Technique(s):
immunofluorescence: 0.25-2 μg/mL
immunohistochemistry: 1:50-1:200
Uniprot accession no.:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Anti-RAB11FIP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab1

biological source

rabbit

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

product line

Prestige Antibodies® Powered by Atlas Antibodies

form

buffered aqueous glycerol solution

species reactivity

human

enhanced validation

orthogonal RNAseq
Learn more about Antibody Enhanced Validation

technique(s)

immunofluorescence: 0.25-2 μg/mL
immunohistochemistry: 1:50-1:200

immunogen sequence

TGSAKHRLHPVKPMNAMATKVANCSLGTATIISENLNNEVMMKKYSPSDPAFAYAQLTHDELIQLVLKQKETISKKEFQVR

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

Quality Level

Gene Information

human ... RAB11FIP1(80223)

Other Notes

Corresponding Antigen APREST76310

Physical form

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Legal Information

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

General description

Rab11-family interacting protein 1 (Rab11-FIP1) is encoded by a gene mapped to human chromosome 8p11. The encoded protein is characterized with an amphipathic a-helix at carboxyl-terminal end involved in binding Rab11a. Rab11-FIP1 and Rab11a, along with other proteins, localize on plasma membrane recycling system vesicles in both non-polarized HeLa cells and polarized madin-darby canine kidney cells (MDCK).

Immunogen

Rab11 family-interacting protein 1 recombinant protein epitope signature tag (PrEST)

Application

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.

Biochem/physiol Actions

Rab11-family interacting protein 1 (Rab11-FIP1) along with Rab11a regulates plasma membrane recycling. Human breast cancer cell lines show elevated expression of Rab11-FIP1 gene. Rab11-FIP1 controls adiponectin trafficking and release from the adipocyte.Rab11-FIP1 expression increases with increasing body mass index (BMI) of humans. Cell-based assay states that Rab11-FIP1A as a potential oncogene plays a role in cell cycle and apoptosis.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:
  • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
  • Protein array of 364 human recombinant protein fragments.

未找到合适的产品?  

试试我们的产品选型工具.

存储类别

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Identification and characterization of a family of Rab11-interacting proteins.
Hales CM
The Journal of Biological Chemistry, 276(42), 39067-39075 (2001)
Cell-based assays suggest role for RAB11FIP1 in cell cycle and apoptosis
Leong WY
Cellular and Molecular Biology, 68(9), 12-16 (2008)
The Rab11-FIP1/RCP gene codes for multiple protein transcripts related to the plasma membrane recycling system.
Jin m and Goldenring JR
Biochimica et Biophysica Acta, 1759(6), 281-295 (2006)
The rab11 effector protein FIP1 regulates adiponectin trafficking and secretion.
Carson BP
PLoS ONE, 8(9) (2013)
Sung Pil Hong et al.
Nature communications, 10(1), 3840-3840 (2019-09-04)
Resistant tumours are thought to arise from the action of Darwinian selection on genetically heterogenous cancer cell populations. However, simple clonal selection is inadequate to describe the late relapses often characterising luminal breast cancers treated with endocrine therapy (ET), suggesting

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持